A first-in-human, phase I, single-center, open-label, dose-escalation trial in healthy volunteers to assess safety, tolerability, and immunogenicity of PANHPVAX, a vaccine targeting human papilloma L2 antigen formulated with cyclic di-AMP

2024-511493-67-00 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 7 Oct 2022 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 45
Countries 1
Sites 1

Prophylactic vaccination against HPV in healthy volunteers

Key facts

Sponsor
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Virus Diseases [C02]
Trial duration
7 Oct 2022 → ongoing
Decision date (initial)
2024-06-06
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-511493-67-00
EudraCT number
2021-002584-22
ClinicalTrials.gov
NCT05208710

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Prophylactic vaccination against HPV in healthy volunteers

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Sponsor organisation
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Address
Im Neuenheimer Feld 280, Neuenheim Neuenheim
City
Heidelberg
Postcode
69120
Country
Germany

Scientific contact point

Organisation
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Contact name
Scientific Trial Coordination

Public contact point

Organisation
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Contact name
Scientific Trial Coordination

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 45 1
Rest of world 0

Investigational sites

Germany

1 site · Ongoing, recruiting
Universitaetsklinikum Heidelberg AöR
Department of Clinical Pharmacology and Pharmacoepidemiology, Im Neuenheimer Feld 410, Neuenheim, Heidelberg

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2022-10-07 2022-10-07

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-28 Germany Acceptable
2024-06-06
2024-06-06
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-04-28 Germany Acceptable
2024-06-06
2025-04-28